Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of RO4389620 in type 2 diabetes (extension of BM18248/BM18249)
2005-004268-21Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of piragliatin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Roche. Primary endpoint: Safety and tolerability of RO4389620 over 52 weeks. Started Dec 2005; status: terminated.
02
Drugs
piragliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-004268-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004268-21.